Fractalkine (CX3CL1) and its receptor (CX3CR1) in children with hypertrophic adenoid and chronic otitis media with effusion

dc.contributor.authorInan, Serhat
dc.contributor.authorBabakurban, Seda Turkoglu
dc.contributor.authorErbek, Selim Sermed
dc.contributor.authorTerzi, Yunus Kasim
dc.contributor.authorSahin, Feride Iffet
dc.contributor.orcID0000-0001-7308-9673en_US
dc.contributor.orcID0000-0001-5067-4044en_US
dc.contributor.orcID0000-0003-4825-3499en_US
dc.contributor.orcID0000-0001-5612-9696en_US
dc.contributor.orcID0000-0001-8821-4481en_US
dc.contributor.researcherIDAAC-7232-2020en_US
dc.contributor.researcherIDAAI-8856-2021en_US
dc.contributor.researcherIDAAJ-1407-2021en_US
dc.contributor.researcherIDB-7604-2019en_US
dc.contributor.researcherIDB-4372-2018en_US
dc.date.accessioned2021-06-21T08:46:26Z
dc.date.available2021-06-21T08:46:26Z
dc.date.issued2020
dc.description.abstractBackground: Adenoid hypertrophy (AH) is one of the possible causes of chronic inflammation in the middle ear. It has been suggested that CX3CL1 and its specific receptor (CX3CR1) could be related with the pathogenesis of some inflammatory diseases. The aim of the present study was to evaluate the role of CX3CL1 and CX3CR1 in the pathogenesis of AH with chronic otitis media with effusion (COME) in children. Materials and methods: Adenoid tissue samples were obtained from 91 pediatric patients and divided into two groups: adenoidectomy only for AH (n: 47) and adenoidectomy in conjunction with ventilation tube insertion for AH + COME (n: 44). Expression levels of CX3CL1 and CX3CR1 genes were compared. Results: Expression levels of CX3CL1 and CX3CR1 in hypertrophic adenoid tissue were not significantly different between the AH + COME and All only groups. Although no significant difference was detected in the expression of CX3CL1 in the adenoid samples, the expression of CX3CR1 was higher in children older than 48 months. Conclusions: When allergy, atopy and chronic adenoiditis does not exist to obstructive adenoid hypertrophy, inflammatory fractalkine chemokine expression levels in adenoid tissue was not observed to be increased in children with COME.en_US
dc.identifier.endpage50en_US
dc.identifier.issn0250-4685en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85083118199en_US
dc.identifier.startpage44en_US
dc.identifier.urihttp://hdl.handle.net/11727/6137
dc.identifier.volume45en_US
dc.identifier.wos000525736100006en_US
dc.language.isoengen_US
dc.relation.isversionof10.1515/tjb-2018-0458en_US
dc.relation.journalTURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISIen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic otitis media with effusionen_US
dc.subjectAdenoid hypertrophiaen_US
dc.subjectFractalkineen_US
dc.subjectCX3CL1en_US
dc.subjectCX3CR1en_US
dc.titleFractalkine (CX3CL1) and its receptor (CX3CR1) in children with hypertrophic adenoid and chronic otitis media with effusionen_US
dc.typearticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: